Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy | recruiting | Phase 3 | 1,450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358182 | Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer | recruiting | — | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 22, 2026 |
| clinicaltrials |
| NCT03879577 | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | active not recruiting | Phase 2 | 53 | University of ChicagoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT05909332 | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | recruiting | Phase 3 | 764 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06220214 | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer | recruiting | Early Phase 1 | 30 | Alison StopeckOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06682195 | Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) | recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07340424 | A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. | recruiting | Early Phase 1 | 15 | Xiaorong SunOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy(neoMono) | terminated | Phase 2 | 442 | Palleos Healthcare GmbHINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06210776 | A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) | recruiting | — | 800 | Daiichi SankyoINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | terminated | Phase 1 | 250 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT07327021 | MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC(NOGA) | recruiting | Phase 2 | 54 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy(ELPIS) | terminated | Phase 2 | 5 | Fundacio Clinic BarcelonaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT06328465 | fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases(fREEDOM) | recruiting | N/A | 145 | European Institute of OncologyOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06418126 | Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer(TNBC-RT2023) | active not recruiting | N/A | 15 | Centre Paul StraussOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06690840 | Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients(AZALEA) | recruiting | Phase 2 | 45 | European Institute of OncologyOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06879704 | Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer(PRECISION) | recruiting | N/A | 115 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer | terminated | Phase 1 | 1 | Baptist Health South FloridaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04148911 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer(EL1SSAR) | completed | Phase 3 | 184 | Hoffmann-La RocheINDUSTRY | 13 | Dec 26, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | terminated | Phase 2 | 24 | University of ChicagoOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299409 | First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. | not yet recruiting | Phase 2 | 24 | Nathalie LevasseurOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT06349512 | 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)(FAP-IT) | recruiting | N/A | 60 | Institut CurieOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06774027 | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer(ENCORE) | recruiting | — | 100 | University of California, San FranciscoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04722978 | Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 228 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05128734 | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07281001 | A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients(Traderrus) | recruiting | N/A | 60 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT02926196 | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab(A-Brave) | completed | Phase 3 | 474 | Istituto Oncologico Veneto IRCCSOTHER | 2 | Dec 12, 2025 | clinicaltrials |
| NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 185 | Seagen Inc.INDUSTRY | 4 | Dec 12, 2025 | clinicaltrials |
| NCT06582615 | Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer(MIND-TNBC) | recruiting | N/A | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer(TrasTUCAN) | terminated | Phase 2 | 13 | Spanish Breast Cancer Research GroupOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07271992 | TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer(TREND-02) | not yet recruiting | Phase 2 | 30 | First Hospital of China Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT06238921 | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | recruiting | Phase 1 / Phase 2 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06817525 | Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC | recruiting | Phase 2 | 64 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04438681 | Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients(INSTIGO) | active not recruiting | — | 90 | Centre Jean PerrinOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05253911 | Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.(TRACE) | completed | — | 49 | iOMEDICO AGINDUSTRY | 2 | Dec 4, 2025 | clinicaltrials |
| NCT05520723 | Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED(PRIMED) | completed | Phase 2 | 50 | MedSIROTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02950259 | Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) | completed | Phase 1 | 16 | Providence Health & ServicesOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05076682 | Reverse Triple Negative Immune Resistant Breast Cancer(Renaissance) | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06735131 | The Optimal Radioimmunotherapy Combinations for Advanced TNBC | recruiting | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06189209 | Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 40 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 22, 2026source: clinicaltrials